Dementia and Alzheimer Disease

The trial will also include another investiartional Eisai agent, the antiamyloid therapy lecanemab, as the background study drug to evaluate the true effect of E2814 has on patients with dominantly inherited Alzheimer disease.

Neurology News Network for the week ending January 22, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 21, 2022.

The study of 251 hospitalized patients with COVID-19 found that biomarkers were elevated to levels that were similar to—or even higher than—those observed in patients with Alzheimer disease.

In cases with reported behavioral variant AD, investigators observed AD-like pattern with relative frontal sparing and a relatively more behavioral variant frontotemporal dementia-like pattern with both posterior and anterior involvement.

The professor of neurology at NYU Langone Grossman School of Medicine discussed future research for neurological complications in patients hospitalized with COVID-19 infection. [WATCH TIME: 4 minutes]

Investigators measured p-tau181 and p-tau231 levels with in-house single molecule array assays and cognition with the Mini-Mental State Examination.

Those who had crossovers of ALS and frontotemporal dementia had structural and functional resemblance to the patterns of damage of those with only behavioral variant frontotemporal dementia.

A recent study found that blood markers of brain damage were higher in patients with COVID-19 than in those with Alzheimer disease. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

The research also identified small subcortical cerebral amyloid angiopathy-associated acute ischemic stroke lesions as risk factors for death in these patients.

Regions typically affected by Alzheimer disease-related neurodegeneration were similarly protected by the carriership of at least 1 ε2 allele, regardless of their load.

Neurology News Network for the week ending January 15, 2022. [WATCH TIME: 4 minutes]

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 14, 2022.

Jennifer Frontera, MD, professor of neurology, NYU Langone Grossman School of Medicine, discussed findings from a recently published study investigating neurological complications in hospitalized patients with COVID-19.

Jeffrey L. Cummings, MD, ScD, comments on the unmet needs and future outlook for the Alzheimer’s treatment landscape.

Dr Cummings relays how testing methods influence the treatment course for Alzheimer’s disease.

Outlining the findings from a recent study comparing SAGE to the Mini-Mental State Examination, the director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center stressed the importance of identifying patients at-risk for dementia early on. [WATCH TIME: 6 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The Anavex Life Sciences treatment was found to be well tolerated in all cohorts of healthy patients with no serious adverse events reported. It is in development for conditions such as frontotemporal dementia.

The director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center discussed benefits of both the pen-and-paper and digital assessments. [WATCH TIME: 7 minutes]

The Centers for Medicare and Medicaid Services issued a proposed decision memo detailing the coverage criteria for patients with Alzheimer disease to be covered by the federal health insurance platform when administered aducanumab (Aduhelm; Biogen).

The director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center discussed motivations behind creating the pen-and-paper test, as well as its digital companion. [WATCH TIME: 2 minutes]

The research assistant professor at the Buffalo Neuroimaging Analysis Center provided context on how different forms of multiple sclerosis impact cognitive decline in patients. [WATCH TIME: 4 minutes]